Categories
Change Password!
Reset Password!
Cannabinoids boost both disease activity and quality of life in people with Crohn's disease and ulcerative colitis. However, they do not affect inflammation levels.
In Crohn's disease (CD) and ulcerative colitis (UC)-affected individuals, using cannabinoids are associated with better quality of life and improved disease activity, though they do not influence inflammation, as elucidated from a recent meta-analysis.
With the escalating authorization of cannabis, enthusiasm has surged regarding its potential role in mitigating inflammatory bowel disease (IBD). Previous meta-analyses have produced inconclusive results, leading to a novel analysis published in “Inflammatory Bowel Diseases” that specifically evaluated the therapeutic effects of cannabinoids in CD and UC.
Researchers Hansol Kang and colleagues searched PubMed, Embase, CENTRAL, and CINAHL for randomized controlled trials examining cannabinoids in CD or UC. Random effects modeling was applied for calculating pooled risk difference estimates, and heterogeneity was gauged via the I² statistic. Eight studies met the inclusion criteria: four focused on CD, three on UC, and one addressed both.
In the CD studies (number of studies: 5), there was a significant reduction in clinical disease activity (risk ratio [RR] = -0.91). However, the pooled analysis for UC did not show considerable improvement (RR = -2.13). Both conditions illustrated improved quality of life (RR = 1.79), but no vital differences were found in endoscopic activity or inflammatory markers.
Inflammatory Bowel Diseases
Meta-analysis of the Therapeutic Impact of Cannabinoids in Inflammatory Bowel Disease
Hansol Kang et al.
Comments (0)